Passage of Federal Right-to-Try law poses risks and opportunities for patients and the biopharmaceutical industry
This Week: House E&C 21st Century Cures Bill Passes Unanimously Out of Committee... House Votes to Codify Permanent R&D Tax Credit... CMS Released Proposed Rule Concerning Medicaid and CHIP Plans....more